From the article: As Marissa Fayer MBA, CEO of Deeplook Medical, adds, a post-mammogram note about breast density puts the onus around patients to decide their next steps and balance risks and costs. Deeplook Medical, in contrast, can give information beyond just breast density to help empower and inform both patients and healthcare providers. This Connecticut-based startup has developed DL Precise™: an FDA-cleared, one-click lesion segmentation, measurement, and visualization tool. In other words, DL Precise™ can take existing regions of interest –like a developing cancerous lesion – and segment and measure those regions as well as colorize them based on density. Since cancerous masses have a higher density than dense breast tissue, they will show up as a different color on the image, making them easily identifiable.
Read more here.